RYTHM (RYM) versus Its Competitors Head-To-Head Review

RYTHM (NASDAQ:RYM) is one of 905 public companies in the “Pharmaceuticals” industry, but how does it compare to its peers? We will compare RYTHM to related companies based on the strength of its institutional ownership, dividends, profitability, risk, earnings, analyst recommendations and valuation.

Volatility and Risk

RYTHM has a beta of 9.44, indicating that its share price is 844% more volatile than the S&P 500. Comparatively, RYTHM’s peers have a beta of -3.18, indicating that their average share price is 418% less volatile than the S&P 500.

Earnings & Valuation

This table compares RYTHM and its peers top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
RYTHM	$17.28 million	-$33.26 million	-2.15
RYTHM Competitors	$16.09 billion	$3.13 billion	546.61

RYTHM’s peers have higher revenue and earnings than RYTHM. RYTHM is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Institutional and Insider Ownership

6.0% of RYTHM shares are held by institutional investors. Comparatively, 32.9% of shares of all “Pharmaceuticals” companies are held by institutional investors. 3.5% of RYTHM shares are held by insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares RYTHM and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
RYTHM	-6.20%	-12.57%	-2.60%
RYTHM Competitors	-2,310.60%	-222.30%	-17.66%

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for RYTHM and its peers, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RYTHM	1	0	0	0	1.00
RYTHM Competitors	7578	13652	25476	994	2.42

As a group, “Pharmaceuticals” companies have a potential upside of 30.41%. Given RYTHM’s peers stronger consensus rating and higher probable upside, analysts plainly believe RYTHM has less favorable growth aspects than its peers.

Summary

RYTHM peers beat RYTHM on 9 of the 13 factors compared.

RYTHM Company Profile

Agrify Corporation develops precision hardware and software cultivation and extraction solutions for the cannabis and hemp industry in the United States. The company offers vertical farming units and Agrify Insights Software-as-a-Service software; integrated grow racks and LED grow lights; and non-proprietary products designed, engineered, and manufactured by third parties, such as air cleaning systems and pesticide-free surface protection products. It also provides associated services comprising consulting, engineering, and construction. The company was formerly known as Agrinamics, Inc. and changed its name to Agrify Corporation in September 2019. Agrify Corporation was incorporated in 2016 and is headquartered in Billerica, Massachusetts.